0001140361-24-015754 | 10-K | XBRL Viewer

Print Document View Excel Document

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2023
Stockholders' Equity [Abstract]
Stockholders' Equity	12. Stockholders’ Equity Preferred Stock The Company is authorized to issue preferred stock with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. Other than the limitations on conversions to keep each such holder’s beneficial ownership below 9.99%, the terms of the Series C convertible preferred stock generally bestow the same rights to each holder as such holder would receive if they were common stock shareholders and are not redeemable by the holders, except that the Series C convertible preferred stock shares do not have voting rights. Each share of Series C convertible preferred stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price equal to $2.69. No preferred shares were outstanding as of December 31, 2023 and 2022. Common Stock The Company issued 337,874 shares upon the vesting of restricted stock during the year ended December 31, 2023. On June 26, 2023, the Company had received written notification from the Nasdaq Stock Market (“Nasdaq”) that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days and that the Company, therefore, was not in compliance with the requirements for continued listing on the Nasdaq Capital Market. On December 27, 2023, the Company received written notice from Nasdaq that it had been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule. The Company issued 358,367 shares to Theravant as consideration for the TheraClear asset acquisition (Note 3) during the year ended December 31, 2022. In October 2021, the Company entered into an equity distribution agreement under which the Company may sell up to $11.0 million of its shares of common stock in registered “at-the-market” offerings. The shares will be offered at prevailing market prices, and the Company will pay commissions of up to 3.0% of the gross proceeds from the sale of shares sold through the Company’s agent, which may act as an agent and/or principal. The Company has no obligation to sell any shares under this agreement and may, at any time, suspend solicitations under this agreement. No shares of the Company’s common stock have been sold under this distribution agreement during fiscal 2023 or 2022. Common Stock Warrants In September 2021 and in connection with entering into the Company’s Senior Term Facility (Note 10), the Company issued a warrant to purchase 373,626 shares of the Company’s common stock at an initial exercise price of $1.82 per share. The warrant was amended in June 2023 in connection with the execution of the Third Amendment to the Senior Term Facility. The amended warrant is to purchase 800,000 shares of the Company’s common stock at an exercise price equal to $0.88 per share. The warrant is equity classified and is exercisable at any time on or prior to the tenth anniversary of its amendment date. As of December 31, 2023, the warrant remains outstanding in its entirety.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Stock-Based Compensation, Restricted Stock Units (Details) - Restricted Stock Units [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Units [Abstract]
Unvested balance at beginning of period (in shares)	119,597	90,540
Granted (in shares)	179,613	187,464
Vested (in shares)	(179,467)	(158,407)
Forfeited and expired (in shares)	(97,089)
Unvested balance at end of period (in shares)	22,654	119,597
Weighted-Average Grant Date Fair Value [Abstract]
Unvested balance at beginning of period (in dollars per share)	$ 0.93	$ 1.45
Granted (in dollars per share)	1.03	0.96
Vested (in dollars per share)	0.96	1.26
Forfeited and expired (in dollars per share)	1.03
Unvested balance at end of period (in dollars per share)	$ 1.03	$ 0.93
Unrecognized Compensation Expense [Abstract]
Weighted average period of recognition	6 months
Maximum [Member]
Unrecognized Compensation Expense [Abstract]
Unrecognized compensation expense	$ 18

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2023

Long-term Debt [Abstract]

Future Payments for Long-term Debt

Future minimum principal payments at December 31, 2023 are as follows (in thousands):

Years ending December 31:
2026	$	3,750
2027		7,500
2028		3,750
		15,000
Exit fee		450
		15,450
Less: unamortized debt discount		(406	)
Long-term debt, net	$	15,044

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,784	$ 5,434
Restricted cash	1,334	1,361
Accounts receivable, net of allowance for credit losses of $222 and $382 at December 31, 2023 and 2022, respectively	4,440	4,471
Inventories	2,673	3,095
Prepaid expenses and other current assets	312	691
Total current assets	15,543	15,052
Property and equipment, net	11,778	9,950
Operating lease right-of-use assets	626	975
Intangible assets, net	7,319	17,394
Goodwill	6,519	8,803
Other assets	231	98
Total assets	42,016	52,272
Current liabilities:
Accounts payable	3,343	3,425
Accrued expenses and other current liabilities	6,306	6,555
Deferred revenues	2,120	2,778
Current portion of operating lease liabilities	352	355
Current portion of contingent consideration	53	313
Total current liabilities	12,174	13,426
Long-term debt, net	15,044	7,476
Deferred revenues and other liabilities	552	314
Deferred tax liability	186	306
Operating lease liabilities, net of current portion	237	610
Contingent consideration, net of current portion	1,135	8,309
Total liabilities	29,328	30,441
Commitments and contingencies (Note 11)
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 35,060,920 and 34,723,046 shares issued and outstanding at December 31, 2023 and 2022, respectively	35	35
Additional paid-in capital	250,711	249,024
Accumulated deficit	(238,058)	(227,228)
Total stockholders' equity	12,688	21,831
Total liabilities and stockholders' equity	$ 42,016	$ 52,272

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (10,830)	$ (5,549)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,553	5,293
Impairment expense	2,284	0
Amortization of operating lease right-of-use assets	349	395
Amortization of deferred financing costs and debt discount	140	157
Change in allowance for credit losses	(110)	107
Stock-based compensation expense	1,303	1,466
Loss on debt extinguishment	909	0
Loss on disposal of property and equipment	72	52
Deferred income taxes	(120)	40
Changes in operating assets and liabilities:
Accounts receivable	141	(1,145)
Inventories	689	(1,340)
Prepaid expenses and other assets	246	(111)
Accounts payable	(100)	603
Accrued expenses and other liabilities	(197)	229
Deferred revenues	(472)	(644)
Operating lease liabilities	(376)	(477)
Net cash used in operating activities	(519)	(924)
Cash flows from investing activities:
Purchase of property and equipment	(5,019)	(3,736)
Cash paid in connection with TheraClear asset acquisition	0	(631)
Net cash used in investing activities	(5,019)	(4,367)
Cash flows from financing activities:
Proceeds from long-term debt	7,000	0
Payment of deferred financing costs	(97)	0
Payment of contingent consideration	(42)	(500)
Net cash provided by (used in) financing activities	6,861	(500)
Net increase (decrease) in cash, cash equivalents and restricted cash	1,323	(5,791)
Cash, cash equivalents and restricted cash at beginning of year	6,795	12,586
Cash, cash equivalents and restricted cash at end of year	8,118	6,795
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	1,415	744
Cash paid during the year for income taxes	22	19
Supplemental schedule of non-cash operating, investing and financing activities:
Modification of common stock warrants	384	0
Transfer of property and equipment to inventories	267	463
Change in intangible assets and fair value of contingent consideration	7,374	0
Accrued exit fee recorded as debt discount	450	0
Accrued payment of contingent consideration	18	0
Inventories acquired in connection with TheraClear asset acquisition	0	71
Intangible assets acquired in connection with TheraClear asset acquisition	0	10,182
Contingent consideration issued in connection with TheraClear asset	0	9,122
Common stock issued in connection with TheraClear asset acquisition	0	500
Change in operating lease right-of-use assets and liabilities due to new and amended leases	$ 0	$ 732

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Remaining Performance Obligation (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 0.7	$ 0.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations		$ 0.4
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 0.3
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	3 years

Stock-Based Compensation

12 Months Ended

Dec. 31, 2023

Stock-Based Compensation [Abstract]

Stock-Based Compensation

13. Stock-Based Compensation

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of December 31, 2023, there were 1,329,375 shares of common stock remaining available for issuance for awards under the 2016 Plan.

The Company measures share‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded share‑based compensation expense (for all awards and modifications, if any) in the accompanying consolidated statements of operations as follows (in thousands):

	Year Ended December 31,
	2023		2022
Selling and marketing	$	79	$	203
General and administrative		1,224		1,263
	$	1,303	$	1,466

On April 3, 2023 and March 30, 2022, the Company granted 150,000 and 160,000 stock-based options, respectively, to its former Chief Executive Officer. The vesting of these awards was contingent upon meeting one or more financial goals (a performance condition) or a common stock share price (a market condition). The fair value of stock-based awards is determined at the date of grant. Stock-based compensation expense is recorded ratably for market condition awards during the requisite service period and is not reversed, except for forfeitures, at the vesting date regardless of whether the market condition is met. Stock-based compensation expense for performance condition awards is re-evaluated at each reporting period based on the probability of the achievement of the goal. The market condition was not met for the 2022 awards and 60,000 of the stock-based options were forfeited during 2022. The 150,000 stock-based options awarded in 2023 were forfeited by December 31, 2023 due to the Chief Executive Officer’s separation and failure to achieve the vesting conditions.

Also in connection with the separation of the Company’s Chief Executive Officer in October 2023, the vesting of 272,098 unvested options to purchase shares of common stock was accelerated. As this acceleration of vesting occurred in accordance with the terms of the original option agreement, it is not considered a modification for accounting purposes. The Company recognized $0.3 million of share-based compensation expense in connection with the accelerated vesting.

Stock Options

The following table summarizes stock option activity for the years ended December 31, 2023 and 2022:

	Number of Shares Under Option Plan			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2022		3,938,613		$	1.90
Granted		1,000,000			1.41
Exercised		(15,000	)		1.29
Forfeited and expired		(448,899	)		2.63
Outstanding at December 31, 2022		4,474,714		$	1.72		8.02
Granted		4,545,069			0.63
Forfeited and expired		(1,291,062	)		1.56
Outstanding at December 31, 2023		7,728,721			1.11		6.70
Exercisable at December 31, 2023		1,256,062		$	1.75		2.09

The weighted‑average grant date fair value of options granted was $0.44 and $1.06 per share during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $2.1 million, which the Company expects to recognize over a weighted‑average period of approximately 3.1 years. The aggregate intrinsic value of options outstanding at December 31, 2023 was $0.1 million. There was no aggregate intrinsic value of options exercisable at December 31, 2023 and no options were exercised during the year ended December 31, 2023. There was no aggregate intrinsic value of options outstanding and options exercisable at December 31, 2022 or of options that were exercised during the year ended December 31, 2022.

The fair value of options is estimated using the Black-Scholes option pricing model which takes into account inputs such as the exercise price, the value of the underlying common stock at the grant date, expected term, expected volatility, risk free interest rate and dividend yield. The fair value of each grant of options during the year ended December 31, 2023 and 2022 was determined using the methods and assumptions discussed below.

●

The expected term of employee options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Options expire up to a maximum of ten years from the date of grant.

●

The expected volatility is based on historical volatility of the Company’s common stock.

●

The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

●

The expected dividend yield is none because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its shares of common stock.

For the years ended December 31, 2023 and 2022, the grant date fair value of all option grants was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:

	Year Ended December 31,
	2023			2022
Expected term (in years)		7.49			6.10
Expected volatility		74.58	%		89.57	%
Risk-free rate		4.38	%		2.51	%
Dividend rate		0.00	%		0.00	%

Restricted Stock Units

Restricted stock units have been issued to certain board members. Activity in restricted stock units is summarized in the following table:

	Number of Units			Weighted- Average Grant Date Fair Value
Unvested at January 1, 2022		90,540		$	1.45
Granted		187,464			0.96
Vested		(158,407	)		1.26
Unvested at December 31, 2022		119,597		$	0.93
Granted		179,613			1.03
Vested		(179,467	)		0.96
Forfeited and expired		(97,089	)		1.03
Unvested at December 31, 2023		22,654		$	1.03

As of December 31, 2023, the total unrecognized compensation expense related to unvested restricted stock units was $18 thousand, which the Company expects to recognize over a weighted‑average period of approximately 0.5 years.

Stock-Based Compensation, Stock Options (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Shares under Options Plan [Abstract]
Outstanding at beginning of period (in shares)	4,474,714	3,938,613
Granted (in shares)	4,545,069	1,000,000
Exercised (in shares)		(15,000)
Forfeited and expired (in shares)	(1,291,062)	(448,899)
Outstanding at end of period (in shares)	7,728,721	4,474,714
Exercisable at end of period (in shares)	1,256,062
Weighted Average Exercise Price per Option [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 1.72	$ 1.9
Granted (in dollars per share)	0.63	1.41
Exercised (in dollars per share)		1.29
Forfeited and expired (in dollars per share)	1.56	2.63
Outstanding at end of period (in dollars per share)	1.11	$ 1.72
Exercisable at end of period (in dollars per share)	$ 1.75
Weighted average remaining contractual term [Abstract]
Outstanding	6 years 8 months 12 days	8 years 7 days
Exercisable	2 years 1 month 2 days
Weighted-average grant date fair value (in dollars per share)	$ 0.44	$ 1.06
Unrecognized compensation expense	$ 2,100,000
Unrecognized compensation expense, weighted average period	3 years 1 month 6 days
Aggregate intrinsic value of options outstanding	$ 100	$ 0
Aggregate intrinsic value of options exercisable	0	0
Aggregate intrinsic value of options exercised	$ 0	$ 0
Maximum [Member]
Weighted average remaining contractual term [Abstract]
Expiration period	10 years

Stockholders' Equity, Outstanding Common Stock Warrants (Details) - Senior Term Facility [Member] - $ / shares	1 Months Ended
	Jun. 30, 2023	Sep. 30, 2021
Warrants and Rights [Abstract]
Warrants issued (in shares)	800,000	373,626
Exercise price (in dollars per share)	$ 0.88	$ 1.82

Asset Acquisition

12 Months Ended

Dec. 31, 2023

Asset Acquisition [Abstract]

Acquisitions

3. Asset Acquisition

In January 2022, the Company acquired certain assets related to the TheraClear devices from Theravant Corporation (“Theravant”). The TheraClear asset acquisition allows the Company to further develop, commercialize and market the TheraClear devices that are used for acne treatment, as well as advance the TheraClear technology into multiple other devices that can be used to treat a range of additional indications.

The Company made an upfront cash payment of $0.5 million and issued to Theravant 358,367 shares of common stock with an aggregate value of $0.5 million as of the closing date in connection with the TheraClear asset acquisition. During the fourth quarter of 2022, the Company also made a $0.5 million milestone payment upon the launch of the TheraClear Acne Therapy System, one of the development-related targets. Theravant is eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones ($1.0 million of which is due upon the earlier of achieving a revenue target or July 2025), up to $20.0 million in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $0.5 million in future milestone payments upon the achievement of certain commercialization related targets. Through December 31, 2023, the Company has incurred $0.1 million of royalty and gross profit payments based on gross profit from domestic and international sales.

The Company determined this transaction represented an asset acquisition as substantially all of the value was in the TheraClear technology intangible asset as defined by ASC 805, Business Combinations.

The purchase price was allocated, on a relative fair value basis, to the technology intangible asset and acquired inventories as follows (in thousands):

Consideration:
Cash payment	$	500
Common stock issued		500
Transaction costs		131
Contingent consideration		9,122
Total consideration	$	10,253

Assets acquired:
Technology intangible asset	$	10,182
Inventories		71
Total assets acquired	$	10,253

The technology intangible asset is being amortized on a straight-line basis over a period of ten years, to be updated for subsequent changes in the contingent consideration that is allocated to its carrying value. The intangible asset was valued using the relief from royalty method. Significant assumptions used in the relief from royalty method include a 14.5% weighted average cost of capital and 15.0% of revenues for the royalty rate. The net book value of acquired inventories approximated its fair value. To calculate the fair value of the earnout using Monte Carlo simulations, Company projections were utilized to develop expected revenues and gross profits based on the risk inherent in the projections using the Geometric-Brownian motion for the earnout periods and related earnout payments. Significant assumptions used in the Geometric-Brownian motion analysis include projected revenues, projected gross profit, risk free rate of return of 1.6%, revenue volatility of 45.0%, and a cost of equity of 10.5%. Due to uncertainties associated with the development of a new product line and the use of estimates and assumptions to determine the fair value of the contingent consideration, the amount ultimately paid in connection with the earnout may differ from the estimated fair value at the acquisition date. A revaluation of the contingent consideration would only be required if there is a significant change to the underlying valuation assumptions. The contingent consideration will be adjusted when the contingency is resolved and the consideration is paid or becomes payable. Any difference between the cash payment and the amount accrued for contingent consideration will result in an adjustment to the technology intangible asset. Contingent consideration expected to be paid within the next year is classified as current on the consolidated balance sheet.

During 2023, the Company revised its projections of expected revenues and gross profits to be earned from TheraClear devices. The change in projections was considered significant enough to warrant a revaluation of the contingent consideration. To calculate the fair value of the earnout at December 31, 2023, using Monte Carlo simulations, Company projections were utilized to develop expected revenues and gross profits based on the risk inherent in the projections using the Geometric-Brownian motion for the earnout periods and related earnout payments. Significant assumptions used in the Geometric-Brownian motion analysis include projected revenues, projected gross profit, risk free rate of return of 3.8%, revenue volatility of 15.0%, and a cost of equity of 10.0%. The fair value of the contingent consideration as of December 31, 2023 was estimated to be $1.2 million, which resulted in a reduction in contingent consideration of $7.4 million with a corresponding adjustment to the carrying value of the technology intangible asset.

Basis of Presentation and Summary of Significant Accounting Policies, Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	8,551,375	5,126,344
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	7,728,721	4,474,714
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	800,000	373,626
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	22,654	278,004

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Lessee, Operating Lease, Description [Abstract]
Increase in ROU asset and operating lease liability resulting from lease modification	$ 700	$ 0
Operating lease costs	400	400
Cash paid for amounts included in measurement of operating lease liabilities	$ 400	$ 400
Weighted average incremental borrowing rate	8.60%	8.76%
Weighted average remaining lease term	2 years	2 years 9 months 18 days
Operating Lease Maturities [Abstract]
2024	$ 386
2025	195
2026	55
Total remaining lease payments	636
Less: imputed interest	(47)
Total lease liabilities	$ 589
Minimum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	1 year
Maximum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	3 years
Facility One [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term	2 years

Organization and Nature of Business (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2021	Dec. 31, 2023
MidCap Financial Trust [Member] \| Senior Term Facility [Member]
Liquidity and Going Concern [Abstract]
Term loan		$ 8.0
MidCap Financial Trust [Member] \| Senior Term Facility One [Member]
Liquidity and Going Concern [Abstract]
Term loan		8.0
MidCap Financial Trust [Member] \| Senior Term Facility Two [Member]
Liquidity and Going Concern [Abstract]
Term loan		7.0
MidCap Financial Trust [Member] \| Senior Term Facility Three [Member]
Liquidity and Going Concern [Abstract]
Term loan		$ 5.0
At-the-Market Equity Offering [Member] \| Maximum [Member]
Liquidity and Going Concern [Abstract]
Amount of common stock the Company may sell under equity distribution agreement	$ 11.0

Inventories (Tables)

12 Months Ended

Dec. 31, 2023

Inventories [Abstract]

Inventories

Inventories consist of the following (in thousands):

	December 31,
	2023		2022
Raw materials and work-in-process	$	2,192	$	2,966
Finished goods		481		129
	$	2,673	$	3,095

Basis of Presentation and Summary of Significant Accounting Policies, Impairment of Long-Lived Assets and Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Impairment of Long-Lived Assets and Intangibles [Abstract]
Asset impairment charges	$ 0	$ 0

Business and Geographical Reporting Segments, Total Assets by Reportable Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Total Assets by Reportable Segment [Abstract]
Assets	$ 42,016	$ 52,272
Non-US [Member]
Long-lived Assets [Abstract]
Long-lived assets	800	600
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Total Assets by Reportable Segment [Abstract]
Assets	28,137	37,230
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Total Assets by Reportable Segment [Abstract]
Assets	5,507	7,890
Other Unallocated Assets [Member]
Total Assets by Reportable Segment [Abstract]
Assets	$ 8,372	$ 7,152

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

+ Details

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned subsidiary in India. No operating activities have occurred within the Company’s subsidiary as of and during the years ended December 31, 2023 and 2022.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation, including the reclassification of lasers-in-process from raw materials and work-in-process inventories and finished goods inventories to property and equipment, net on the consolidated balance sheet.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.

Concentrations of Credit Risk and Major Customers

The Company’s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $0.3 million per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little credit risk to the Company.

Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers.

The Company had one and two customers, international distributors, from which it earns dermatology recurring procedures and dermatology procedures equipment revenues, that accounted for 10% or more of the Company’s revenues for the years ended December 31, 2023 and 2022, respectively. Revenues from these customers were $3.3 million and $8.5 million, or 10% and 23%, of total net revenues during the years ended December 31, 2023 and 2022, respectively. Accounts receivable associated with these customers was nil as of December 31, 2023 and $0.5 million, or 11%, of net accounts receivable as of December 31, 2022. One other customer had $0.7 million, or 16.5%, of net accounts receivable as of December 31, 2023. No other customer represented more than 10% of total accounts receivable as of December 31, 2022.

Cash and Cash Equivalents

The Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2023 and 2022, cash equivalents consisted of credit card transactions with settlement terms of less than five days.

Restricted Cash

As discussed more fully in Note 11, an administrative state judge in the State of New York issued an opinion in January 2021 finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, the Company received a written decision from the State of New York Tax Appeals Tribunal (“Tribunal”) overturning the favorable sales tax determination of the administrative law judge. The Company appealed the Tribunal’s decision to the New York State Appellate Division (“Appellate Division”), and posted the required appellate bond in the form of cash collateral. Oral argument was held by the Appellate Division on January 18, 2024.

On March 8, 2024, the Company received a decision from the Appellate Division ruling against it in the matter of its sales tax appeal, affirming the Tribunal’s ruling that the Company’s sale of XTRAC treatment codes is subject to sales tax. The Appellate Division concluded that, through the usage arrangements, the Company’s customers had possession of the laser devices and had a license and ability to use the laser devices. The Appellate Division also agreed with the Tribunal that the primary function analysis was not applicable in this matter. The Company will be filing a motion to appeal the Appellate Division’s decision.

The cash collateral is recorded as restricted cash on the consolidated balance sheets as of December 31, 2023 and 2022. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2023		2022
Cash and cash equivalents	$	6,784	$	5,434
Restricted cash		1,334		1,361
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,118	$	6,795

Accounts Receivable and Allowance for Credit Losses

Accounts receivable primarily relates to amounts due from customers, which are typically due within 30 to 90 days from invoice date. The Company provides credit to its customers in the normal course of business and maintains allowances for expected credit losses over the remaining contractual lives of its receivables, considering customer financial condition, historical loss experience with customers, current market economic conditions and forecasts of future economic conditions when appropriate. The Company does not require collateral or other security for accounts receivable. The Company also maintains allowances for estimated losses resulting from amounts deemed to be uncollectible from its customers. These allowances are for specific amounts on certain customer accounts based on facts and circumstances determined on a case-by-case basis. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to bad debt expense. The Company does not recognize interest accruing on accounts receivable past due.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined based on purchased cost for raw materials and all production cost related to the laser manufacturing process (labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods is classified as inventory. For the Company’s products, cost is determined on the first-in, first-out method. Work-in-process is immaterial, given the typically short manufacturing cycle and therefore, is disclosed in conjunction with raw materials.

The Company’s equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician’s office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser for sale is accumulated in inventory, and the cost to build a laser for placement is accumulated in property and equipment.

Reserves for slow-moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends.

Property and Equipment, net

Property and equipment are recorded at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Upon retirement or disposition, the applicable property and equipment amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of operations. Depreciation and amortization are recognized using the straight-line method based on the estimated useful lives of the related assets. The Company uses an estimated useful life of three years for computers, hardware and software, five years for machinery and equipment and seven years for furniture and fixtures and the lesser of the useful life or lease term for leasehold improvements.

Intangible Assets

Intangible assets consist of core technology, product technology, customer relationships, trademarks and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to 12 years.

Goodwill

Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has two reporting units and goodwill is allocated to the reporting units (see Note 15).

The Company performs its goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded for the amount by which the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. In conjunction with the annual budgeting process during the fourth quarter of 2023 and using data collected since the official launch of the TheraClear devices, the Company reduced its projected earnings from TheraClear devices (see Note 3). As a result, the Company bypassed the qualitative assessment of goodwill impairment and performed a quantitative assessment by comparing the fair value of each reporting unit with its carrying amount. The Company recorded a $2.3 million impairment charge related to goodwill, which was the amount of the excess of the carrying value of the dermatology recurring procedures reporting unit over its fair value. The impairment was primarily driven by a decline in projected cash flows, including revenues and profitability. The fair values of the reporting units were determined using both a market and income approach, with the market approach given a 25% weighting and the income approach given a 75% weighting. Significant assumptions used in the income approach include growth and discount rates, profit margins and the Company’s weighted average cost of capital. Historical performance and management estimates of future performance were used to determine profit margins and growth rates.

The impairment charge is included in impairment of goodwill within the consolidated statement of operations for the year ended December 31, 2023. The dermatology procedures equipment reporting unit was not identified as having impairment for the year ended December 31, 2023. The Company’s annual goodwill impairment test resulted in no impairment charge during the year ended December 31, 2022.

Impairment of Long-Lived Assets and Intangibles

The Company reviews its long-lived assets and intangible assets subject to amortization for impairment whenever events or changes in circumstances indicate the carrying amount of an asset group may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset group to future net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group, less costs to sell. The Company did not record any charges related to asset impairment during the years ended December 31, 2023 and 2022.

Fair Value Measurements

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

•	Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold.

The activity in the warranty accrual during the years ended December 31, 2023 and 2022 is summarized as follows (in thousands):

	December 31,
	2023			2022
Balance, beginning of year	$	207		$	79
Additions		237			246
Expirations and claims satisfied		(141	)		(118	)
Total		303			207
Less current portion within accrued expenses and other current liabilities		(180	)		(136	)
Balance within deferred revenues and other liabilities	$	123		$	71

Debt Issuance Costs

The Company capitalizes direct costs incurred to obtain debt financing and amortizes these costs to interest expense over the term of the debt using the effective interest method. These costs are recorded as a debt discount and are netted against the related debt on the Company’s consolidated balance sheets.

Revenue Recognition

Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

Revenues from the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.

Revenues from dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2023		2022
Dermatology recurring procedures	$	21,530	$	23,025
Dermatology procedures equipment		11,828		13,136
Total net revenues	$	33,358	$	36,161

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements (in thousands):

Years ending December 31:
2024	$	1,319
2025		787
2026		569
2027		298
	$	2,973

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties and service contracts but exclude any dermatology procedures equipment accounted for as leases. As of December 31, 2023 and 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $0.7 million and $0.6 million, respectively, and the Company expects to recognize $0.3 million and $0.4 million, respectively, of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.

Contract liabilities primarily relate to extended warranties and service contracts where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of standalone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of December 31, 2023 and 2022, the $0.3 million and $0.4 million of short-term contract liabilities, respectively, is presented as deferred revenues and the $0.4 million and $0.2 million of long-term contract liabilities, respectively, is presented within deferred revenues and other liabilities on the consolidated balance sheets. For the years ended December 31, 2023 and 2022, the Company recognized $0.4 million and $0.9 million, respectively, as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2022 and 2021.

With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Advertising costs are expensed as incurred and included in selling and marketing expenses within the Company’s consolidated statement of operations. The Company recognized advertising costs of $0.5 million and $1.6 million during the years ended December 31, 2023 and 2022, respectively.

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The estimated fair value of restricted stock awards is equal to the Company’s common stock price at the grant date. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of stock-option awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities, as well as on net operating loss carryforwards, and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is not more likely than not that all or some portion of the deferred tax asset will be realized.

The Company recognizes the tax effects of uncertain tax positions only if the position is “more-likely-than-not” to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the “more-likely-than-not” threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded. The Company has no uncertain tax positions as of December 31, 2023. The Company includes interest and penalties related to income tax obligations within income tax expense. The Company’s tax years are still under open status from 2020 to present.

Net Loss Per Share

Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2023		2022
Stock options		7,728,721		4,474,714
Common stock warrants		800,000		373,626
Restricted stock units		22,654		278,004
		8,551,375		5,126,344

Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted

Accounting Pronouncements Recently Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as amended subsequently by ASUs 2018-19, 2019-04, 2019-05, 2019-10, 2019-11 and 2020-03. The guidance in the ASUs requires that credit losses be reported using an expected losses model rather than the incurred losses model that was previously used. The standard also establishes additional disclosures related to credit risks. This standard was effective for fiscal years beginning after December 15, 2022. The adoption of this guidance on January 1, 2023 did not have a material effect on the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s own Equity. The pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for it and simplifies the diluted earnings per share (EPS) calculations in certain areas. The guidance is effective for annual periods, including interim periods, beginning after December 15, 2023 and early adoption is permitted. The Company does not currently believe it will have a material effect on its consolidated financial statements, but it could in the future.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which will primarily require enhanced disclosures about significant segment expenses and information used to assess segment performance and enhanced disclosures in interim periods. The guidance in this ASU will be applied retrospectively and is effective for fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in this ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements.

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	4. Fair Value Measurements The carrying values of cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, and accounts payable on the Company’s consolidated balance sheets approximated their fair values as of December 31, 2023 and 2022 due to their short-term nature. The carrying value of the Company’s current Senior Term Facility approximated its fair value as of December 31, 2023 and 2022 due to its variable interest rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Basis of Presentation and Summary of Significant Accounting Policies, Property and Equipment, net (Details)	Dec. 31, 2023
Computers, Hardware and Software [Member]
Property and Equipment, Net [Abstract]
Property and equipment, net, useful life	3 years
Machinery and Equipment [Member]
Property and Equipment, Net [Abstract]
Property and equipment, net, useful life	5 years
Furniture and Fixtures [Member]
Property and Equipment, Net [Abstract]
Property and equipment, net, useful life	7 years

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 36,062	$ 31,906
Less: accumulated depreciation and amortization	(24,284)	(21,956)
Property and equipment, net	11,778	9,950
Depreciation and amortization expense	2,900	2,400
Lasers Placed-In-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	32,095	28,790
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	293	293
Furniture and Fixtures [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	240	235
Leasehold Improvements [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	203	136
Lasers-In-Process [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 3,231	$ 2,452

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Abstract]
Revenues, net	$ 33,358	$ 36,161
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	21,530	23,025
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	$ 11,828	$ 13,136

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of inventory [Abstract]
Raw materials and work-in-process	$ 2,192	$ 2,966
Finished goods	481	129
Inventories, net	$ 2,673	$ 3,095

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Stockholders' Equity, Preferred Stock and Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Class of Stock Disclosures [Abstract]
Preferred stock, stated value (in dollars per share)		$ 0.1	$ 0.1
Preferred shares outstanding (in shares)		0	0
Issuance of restricted stock (in shares)		337,874
Number of shares issued in connection with asset acquisition (in shares)		358,367
At-the-Market Equity Offering [Member]
Class of Stock Disclosures [Abstract]
Common stock sold under equity distribution agreement (in shares)		0	0
At-the-Market Equity Offering [Member] \| Maximum [Member]
Class of Stock Disclosures [Abstract]
Amount of common stock the Company may sell under equity distribution agreement	$ 11.0
Commission as percentage of gross proceeds from sale of shares sold	3.00%
Series C Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Beneficial ownership percentage		9.99%
Preferred stock, stated value (in dollars per share)		$ 1,000
Preferred stock conversion price (in dollars per share)		$ 2.69

Organization and Nature of Business	12 Months Ended
Organization and Nature of Business	Dec. 31, 2023
The Company [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear Acne Therapy System to broaden its opportunities with expansion potential in the acne care market. The Company markets the device under the brand name TheraClear® X. Post-COVID-19 Pandemic Since March 2020, the global pandemic related to a new strain of coronavirus (“COVID-19”) has negatively impacted business conditions in the industry in which the Company operates, disrupted global supply chains, constrained workforce participation and created significant volatility and disruption of financial markets. The pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices, which are the Company’s primary customers. While most offices have reopened, some physician practices closed and never reopened. Accordingly, the COVID-19 pandemic and its variants have negatively impacted the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames and those of its primary customers. It has also negatively impacted the Company’ supply chains and transport, customer behavior and staffing. Impact of Russia-Ukraine War Prior to the outbreak of the Russia-Ukraine War, Ukraine was the largest exporter of noble gases including neon, krypton, and xenon and has historically been the source of a significant amount of gas supplied to the Company by its contract suppliers. Neon gas is essential to the proper functioning of the Company’s lasers. The Company’s suppliers have been resourceful in continuing to supply gases to the Company but cannot assure the Company that the supply will remain uninterrupted. The reduced supply and ongoing conflict have also impacted the price of gas worldwide. Additionally, the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 has led to a further tightening of rare gas supplies as semiconductor chip manufacturers reconfigure their supply chains to address the need to secure their own supplies of rare gases for use in the manufacture of computer chips. Liquidity and Going Concern The Company has been negatively impacted by the COVID-19 pandemic, has historically experienced recurring losses, has been dependent on raising capital from the sale of securities in order to continue to operate and has been required to restrict cash for potential sales tax liabilities (see Note 11). In October 2021, the Company entered into an equity distribution agreement with an investment bank under which the Company may sell up to $11.0 million of its common stock in registered “at-the-market” offerings. In June 2023, the Company amended its credit facility with MidCap Financial Trust to: (i) refinance its existing $8.0 million term loan, (ii) borrow an additional $7.0 million, and (iii) provide for an additional $5.0 million tranche that can be drawn under certain conditions in 2024. Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of its products and operating expense management, will be sufficient to satisfy the Company’s working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these consolidated financial statements. However, market conditions, including the negative impact of the COVID-19 pandemic, the Russia-Ukraine War, and the Israel-Hamas conflict on the financial markets, supply chain disruptions, customer behavior, and rising interest rates, could interfere with the Company’s ability to access financing and on favorable terms.

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2023
Lasers Placed-in Service [Member]
Revenue Recognition [Abstract]
Lease term	36 months
Renewal term	1 year
Lasers Placed-in Service [Member] \| Minimum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	30 days
Lasers Placed-in Service [Member] \| Maximum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	60 days
South Korea [Member]
Revenue Recognition [Abstract]
Lease term	48 months

Intangible Assets and Goodwill, Components of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Components of Goodwill [Abstract]
Goodwill	$ 6,519	$ 8,803
Impairment of goodwill	2,284	0
Dermatology Recurring Procedures [Member]
Components of Goodwill [Abstract]
Goodwill	5,674	7,958
Impairment of goodwill	2,300
Dermatology Procedures Equipment [Member]
Components of Goodwill [Abstract]
Goodwill	$ 845	$ 845

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Intangible Assets and Goodwill, Components of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Components of Intangible Assets [Abstract]
Balance	$ 24,222	$ 31,596
Accumulated amortization	(16,903)	(14,202)
Intangible assets, net	7,319	17,394
Amortization expense of intangible assets	2,700	2,900
Reduction in contingent consideration adjusted to carrying value of technology intangible asset	7,400
Core Technology [Member]
Components of Intangible Assets [Abstract]
Balance	5,700	5,700
Accumulated amortization	(4,845)	(4,275)
Intangible assets, net	855	1,425
Product Technology [Member]
Components of Intangible Assets [Abstract]
Balance	4,808	12,182
Accumulated amortization	(3,866)	(3,018)
Intangible assets, net	942	9,164
Customer Relationships [Member]
Components of Intangible Assets [Abstract]
Balance	6,900	6,900
Accumulated amortization	(5,865)	(5,175)
Intangible assets, net	1,035	1,725
Tradenames [Member]
Components of Intangible Assets [Abstract]
Balance	1,500	1,500
Accumulated amortization	(1,275)	(1,125)
Intangible assets, net	225	375
Pharos Customer Lists [Member]
Components of Intangible Assets [Abstract]
Balance	5,314	5,314
Accumulated amortization	(1,052)	(609)
Intangible assets, net	$ 4,262	$ 4,705

Inventories

12 Months Ended

Dec. 31, 2023

Inventories [Abstract]

Inventories

5. Inventories

Inventories consist of the following (in thousands):

	December 31,
	2023		2022
Raw materials and work-in-process	$	2,192	$	2,966
Finished goods		481		129
	$	2,673	$	3,095

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Income Taxes [Abstract]

Components of Income Tax Expense

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2023			2022
Current:
Federal	$	—		$	—
State		28			23
		28			23
Deferred:
Federal		(68	)		23
State		(52	)		17
		(120	)		40
(Benefit from) / provision for income taxes	$	(92	)	$	63

Components of Deferred Tax Liability for Federal Income Taxes

Significant components of the Company’s deferred tax liability for federal income taxes consisted of the following (in thousands):

	December 31,
	2023			2022
Deferred tax assets:
Net operating loss carryforwards	$	46,718		$	45,077
Intangible assets		2,138			1,697
Inventories		71			57
Reserves and accrued expenses		1,381			1,431
Stock-based compensation		180			548
Operating lease liabilities		145			240
Interest expense limitation carryover		552			208
Property and equipment		—			1,111
Gross deferred tax assets		51,185			50,369
Less: valuation allowance		(50,139	)		(49,005	)
		1,046			1,364
Deferred tax liabilities:
Property and equipment		(412	)		—
Operating lease right-of-use assets		(154	)		(242	)
Goodwill		(666	)		(1,095	)
481(a) adjustment		—			(333	)
		(1,232	)		(1,670	)
Net deferred tax liability	$	(186	)	$	(306	)

Net Operating Loss Carryforwards

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
	2023		2022
Federal	$	205,212	$	198,144
State	$	63,566	$	60,784

Reconciliation of Income Tax Expense

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	Year Ended December 31,
	2023			2022
Federal tax expense at statutory rate		21.00	%		21.00	%
State tax, net of federal benefit		0.18	%		(0.58	)%
Permanent differences		(1.89	)%		(2.23	)%
Other difference and true ups		(8.07	)%		(11.20	)%
Change in valuation allowance		(10.38	)%		(8.14	)%
Effective income tax rate		0.84	%		(1.15	)%

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2023		2022
Warranty obligations	$	180	$	136
Compensation and related benefits		1,679		1,997
State sales, use and other taxes		4,316		3,986
Professional fees and other		131		436
	$	6,306	$	6,555

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Future Undiscounted Fixed Treatment Code Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 700	$ 600
Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	2,973
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers		$ 400
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 300
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,319
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 787
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 569
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 298
Expected timing of satisfaction period	1 year

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Stock-Based Compensation [Abstract]

Share-based Compensation Expense

The Company recorded share‑based compensation expense (for all awards and modifications, if any) in the accompanying consolidated statements of operations as follows (in thousands):

	Year Ended December 31,
	2023		2022
Selling and marketing	$	79	$	203
General and administrative		1,224		1,263
	$	1,303	$	1,466

Stock Option Activity

The following table summarizes stock option activity for the years ended December 31, 2023 and 2022:

	Number of Shares Under Option Plan			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2022		3,938,613		$	1.90
Granted		1,000,000			1.41
Exercised		(15,000	)		1.29
Forfeited and expired		(448,899	)		2.63
Outstanding at December 31, 2022		4,474,714		$	1.72		8.02
Granted		4,545,069			0.63
Forfeited and expired		(1,291,062	)		1.56
Outstanding at December 31, 2023		7,728,721			1.11		6.70
Exercisable at December 31, 2023		1,256,062		$	1.75		2.09

Weighted Average Assumption Used for Grant Date Fair Value of Option Grants

	Year Ended December 31,
	2023			2022
Expected term (in years)		7.49			6.10
Expected volatility		74.58	%		89.57	%
Risk-free rate		4.38	%		2.51	%
Dividend rate		0.00	%		0.00	%

Summary of Activity in Restricted Stock Units

Restricted stock units have been issued to certain board members. Activity in restricted stock units is summarized in the following table:

	Number of Units			Weighted- Average Grant Date Fair Value
Unvested at January 1, 2022		90,540		$	1.45
Granted		187,464			0.96
Vested		(158,407	)		1.26
Unvested at December 31, 2022		119,597		$	0.93
Granted		179,613			1.03
Vested		(179,467	)		0.96
Forfeited and expired		(97,089	)		1.03
Unvested at December 31, 2023		22,654		$	1.03

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Legal Matters In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract, and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony, and information in connection with various aspects of its activities. On April 1, 2022, a proposed representative class action under California’s Private Attorneys General Act (“PAGA”) was filed in Superior Court of California, County of San Diego against the Company and an employment agency which provided the Company with temporary employees. The complaint alleges various violations of the California Labor Code, including California’s wage and hour laws, relating to current and former non-exempt employees of the Company. The complaint seeks class status and payments for allegedly unpaid compensation and attorney’s fees. In a related matter, the attorneys in this matter and the proposed class representative, in a letter dated March 12, 2022, to the California Labor & Workforce Development Agency made nearly identical claims seeking the right to pursue a PAGA action against the Company and the employment agency. On or about May 16, 2022, the plaintiff filed a First Amended Complaint adding a PAGA claim to the action. On or about June 2, 2022, the plaintiff filed an Application to Dismiss Class and Individual Claim without prejudice, in an attempt to pursue a PAGA only complaint. On or about June 30, 2022, the parties entered into a stipulation to allow the plaintiff to file a Second Amended Complaint to clarify the PAGA claim and to stay the pending action to allow an attempt at resolution through mediation. The mediation was held on February 23, 2023, and the matter was settled on terms agreeable to the Company. The settlement, which requires the Company to pay $0.1 million, was subject to the right of individual class members to opt out of the settlement and proceed on their own. No individual has requested to opt out of the settlement. As of December 31, 2023, $0.1 million has been accrued for this matter. Sales and Use Tax Matters The Company records state sales tax collected and remitted for its customers on dermatology procedures equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses within the consolidated statements of operations. The Company believes its state sales and use tax accruals have been properly recognized such that, if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state, the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities, as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing, and time period at issue, as well as the final outcome of any audit and actual settlement, remains uncertain. In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The states of New York and California have assessed the Company an aggregate of $3.9 million including penalties and interest. The audits cover the period from March 2014 through November 2022. The Company received notification that an administrative state judge in New York issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. This ruling covers $1.4 million of the total $3.9 million of assessments. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, the Company received a written decision from the Tribunal overturning the favorable sales tax determination of the administrative law judge. The Company appealed the Tribunal’s decision to the Appellate Division, and posted the required appellate bond in the form of cash collateral. Oral argument was held by the Appellate Division on January 18, 2024. On March 8, 2024, the Company received a decision from the Appellate Division ruling against it in the matter of its sales tax appeal, affirming the Tribunal’s ruling that the Company’s sale of XTRAC treatment codes is subject to sales tax. The Appellate Division concluded that, through the usage arrangements, the Company’s customers had possession of the laser devices and had a license and ability to use the laser devices. The Appellate Division also agreed with the Tribunal that the primary function analysis was not applicable in this matter. The Company will be filing a motion to appeal the Appellate Division’s decision. The Company is also in the administrative process of appeal with respect to the remaining $2.5 million of assessments. If there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine, or the Company does not have other defenses where the Company prevails, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties. The precise scope, timing and time periods at issue, as well as the final outcomes of the investigations and judicial proceedings, remain uncertain. Accordingly, the Company’s estimate may change from time to time, and actual losses could vary. Employee 401(k) Savings Plan The Company sponsors a 401(k) defined contribution retirement savings plan that covers all eligible employees who have met the minimum age and service requirements. Under the plan, eligible employees may contribute a portion of their annual compensation into the plan up to IRS annual limits. The Company has elected to make matching contributions to the plan based on a percentage of the employee’s contribution. For the years ended December 31, 2023 and 2022, the Company’s contributions to the plan were $0.4 million and $0.3 million, respectively. Milestone Payments In January 2022, the Company entered into a Development Agreement (the “Development Agreement”) with Theravant. Under the Development Agreement, the Company will reimburse Theravant for costs incurred in further developing certain TheraClear technology and other healthcare products and methods for the medical aesthetic marketplace. In connection with the development of three devices, Theravant is eligible to receive $0.5 million upon FDA clearance for each device and $0.5 million upon achievement of certain net revenue targets for each device, aggregating to $3.0 million of potential future milestone payments under the Development Agreement. The Development Agreement has a three-year term, unless terminated sooner by either party, and is being accounted for separately from the TheraClear asset acquisition discussed in Note 3.

Long-term Debt, Senior Term Facility (Details) $ / shares in Units, $ in Thousands		1 Months Ended		3 Months Ended	12 Months Ended
	Sep. 06, 2022	Jun. 30, 2023 $ / shares shares	Sep. 30, 2021 $ / shares shares	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) Payment $ / shares shares	Dec. 31, 2022 USD ($)
Long-term Debt [Abstract]
Loss on debt extinguishment					$ (909)	$ 0
Unamortized debt discount					406
Exit fee					450
SOFR [Member]
Long-term Debt [Abstract]
Term of variable rate	1 month
Basis spread on variable rate	0.50%
Interest rate floor	0.10%
Senior Term Facility [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares		800,000	373,626
Warrants, exercise price (in dollars per share) \| $ / shares		$ 0.88	$ 1.82
MidCap Financial Trust [Member] \| Senior Term Facility [Member]
Long-term Debt [Abstract]
Face amount of debt					$ 8,000
Maturity date					Sep. 01, 2026
Frequency of payment					monthly
Number of monthly principal payments plus interest \| Payment					24
Notice period					30 days
Prepayment fee if prepayment is made within twelve months					4.00%
Prepayment fee if prepayment is made between twelve months and twenty-four months					3.00%
Prepayment fee if prepayment is made between twenty-four months and thirty-six months					2.00%
Prepayment fee if prepayment is made after thirty-six months					1.00%
Minimum net revenue threshold					$ 29,000
Minimum net revenue threshold by December 31, 2026					33,000
Minimum net revenue threshold by trailing 12-month period					36,000
Minimum unrestricted cash					3,000
Loss on debt extinguishment					900
Unamortized debt discount					400
Increase in fair value of warrants					400
Lender fees					100
Interest expense					1,600	900
Amortization of debt discount					100	$ 200
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| Minimum [Member]
Long-term Debt [Abstract]
Prepayment of debt					$ 5,000
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| Forecast [Member]
Long-term Debt [Abstract]
Minimum net revenue threshold by trailing 12-month period				$ 33,000
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| A&R Warrant [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares					800,000
Warrants, exercise price (in dollars per share) \| $ / shares					$ 0.88
Warrants, expected term					10 years
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| Common Stock [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares					373,626
Warrants, exercise price (in dollars per share) \| $ / shares					$ 1.82
Warrants, expected term					10 years
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| LIBOR [Member]
Long-term Debt [Abstract]
Basis spread on variable rate					7.50%
Interest rate floor					0.50%
MidCap Financial Trust [Member] \| Senior Term Facility, Amendment [Member]
Long-term Debt [Abstract]
Face amount of debt					$ 20,000
Forward looking term					30 days
Interest rate floor					3.50%
Amount available to be drawn under condition					$ 30,000
Effective interest rate					13.68%	11.72%
Required percentage of certain insurance proceeds					100.00%
MidCap Financial Trust [Member] \| Senior Term Facility, Amendment [Member] \| SOFR [Member]
Long-term Debt [Abstract]
Term of variable rate					1 month
Base interest rate					0.10%
Basis spread on variable rate					7.50%
MidCap Financial Trust [Member] \| Credit Facility #1 [Member]
Long-term Debt [Abstract]
Amount drawn					$ 8,000
MidCap Financial Trust [Member] \| Credit Facility #2 [Member]
Long-term Debt [Abstract]
Amount drawn					$ 7,000
Percentage of administrative agent fess					0.50%
Percentage of credit extension					4.00%
MidCap Financial Trust [Member] \| Credit Facility #3 [Member]
Long-term Debt [Abstract]
Amount available for amount drawn					$ 5,000
Percentage of credit extension					0.50%
Percentage of exit fee					4.00%
MidCap Financial Trust [Member] \| Senior Term Facility, Third Amendment [Member]
Long-term Debt [Abstract]
Unamortized debt discount					$ 400	$ 500
Exit fee					500
Third party costs incurred					$ 13
MidCap Financial Trust [Member] \| Senior Term Facility, Fourth Amendment, Credit Facility 1 [Member]
Long-term Debt [Abstract]
Percentage of credit extension					3.00%
MidCap Financial Trust [Member] \| Senior Term Facility, Fourth Amendment, Credit Facility 2 [Member]
Long-term Debt [Abstract]
Percentage of credit extension					3.00%

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In-Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2021	$ 34	$ 247,059	$ (221,679)	$ 25,414
Beginning balance (in shares) at Dec. 31, 2021	34,364,679
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	1,466	0	1,466
Issuance of common stock for acquisition	$ 1	499	0	500
Issuance of common stock for acquisition (in shares)	358,367
Net loss	$ 0	0	(5,549)	(5,549)
Ending balance at Dec. 31, 2022	$ 35	249,024	(227,228)	21,831
Ending balance (in shares) at Dec. 31, 2022	34,723,046
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	1,303	0	1,303
Issuance of restricted stock	$ 0	0	0	$ 0
Issuance of restricted stock (in shares)	337,874			337,874
Modification of common stock warrants	$ 0	384	0	$ 384
Issuance of common stock for acquisition (in shares)				358,367
Net loss	0	0	(10,830)	$ (10,830)
Ending balance at Dec. 31, 2023	$ 35	$ 250,711	$ (238,058)	$ 12,688
Ending balance (in shares) at Dec. 31, 2023	35,060,920

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Warranty obligations	$ 180	$ 136
Compensation and related benefits	1,679	1,997
State sales, use and other taxes	4,316	3,986
Professional fees and other	131	436
Accrued expenses and other current liabilities	$ 6,306	$ 6,555

Basis of Presentation and Summary of Significant Accounting Policies, Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Unit	Dec. 31, 2022 USD ($)
Goodwill [Abstract]
Number of reporting units \| Unit	2
Goodwill impairment \| $	$ 2,284	$ 0
Market Approach [Member]
Goodwill [Abstract]
Percentage of fair value weighting market approach given	25.00%
Income Approach [Member]
Goodwill [Abstract]
Percentage of fair value weighting market approach given	75.00%

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2023

Intangible Assets and Goodwill [Abstract]

Components of Intangible Assets

Intangible assets consist of the following (in thousands):

December 31, 2023	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(4,845	)	$	855
Product technology		4,808		(3,866	)		942
Customer relationships		6,900		(5,865	)		1,035
Tradenames		1,500		(1,275	)		225
Pharos customer lists		5,314		(1,052	)		4,262
	$	24,222	$	(16,903	)	$	7,319

December 31, 2022	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(4,275	)	$	1,425
Product technology		12,182		(3,018	)		9,164
Customer relationships		6,900		(5,175	)		1,725
Tradenames		1,500		(1,125	)		375
Pharos customer lists		5,314		(609	)		4,705
	$	31,596	$	(14,202	)	$	17,394

Estimated Future Amortization Expense for Intangible Assets

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2024			1,971
2025			1,266
2026			561
2027			561
2028			561

Components of Goodwill

Goodwill consists of the following (in thousands):

	December 31,
	2023		2022
Dermatology recurring procedures segment	$	5,674	$	7,958
Dermatology procedures equipment segment		845		845
	$	6,519	$	8,803

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2023

Property and Equipment, net [Abstract]

Components of Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31,
	2023			2022
Lasers placed-in-service	$	32,095		$	28,790
Equipment, computer hardware and software		293			293
Furniture and fixtures		240			235
Leasehold improvements		203			136
Lasers-in-process		3,231			2,452
		36,062			31,906
Less: accumulated depreciation and amortization		(24,284	)		(21,956	)
	$	11,778		$	9,950

Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Reclassifications

Use of Estimates

Concentrations of Credit Risk and Major Customers

Cash and Cash Equivalents

Restricted Cash

	December 31,
	2023		2022
Cash and cash equivalents	$	6,784	$	5,434
Restricted cash		1,334		1,361
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,118	$	6,795

Accounts Receivable and Allowance for Credit Losses

Inventories

Property and Equipment, net

Intangible Assets

Goodwill

Impairment of Long-Lived Assets and Intangibles

Fair Value Measurements

•	Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The activity in the warranty accrual during the years ended December 31, 2023 and 2022 is summarized as follows (in thousands):

	December 31,
	2023			2022
Balance, beginning of year	$	207		$	79
Additions		237			246
Expirations and claims satisfied		(141	)		(118	)
Total		303			207
Less current portion within accrued expenses and other current liabilities		(180	)		(136	)
Balance within deferred revenues and other liabilities	$	123		$	71

Debt Issuance Costs

Revenue Recognition

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2023		2022
Dermatology recurring procedures	$	21,530	$	23,025
Dermatology procedures equipment		11,828		13,136
Total net revenues	$	33,358	$	36,161

Years ending December 31:
2024	$	1,319
2025		787
2026		569
2027		298
	$	2,973

With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Income Taxes

Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2023		2022
Stock options		7,728,721		4,474,714
Common stock warrants		800,000		373,626
Restricted stock units		22,654		278,004
		8,551,375		5,126,344

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

Long-term Debt, Future Minimum Principal Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Future Payments for Long-Term Debt [Abstract]
2026	$ 3,750
2027	7,500
2028	3,750
Total	15,000
Exit fee	450
Long term debt after exit fee	15,450
Less: unamortized debt discount	(406)
Long-term debt, net	$ 15,044	$ 7,476

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Operating Lease Maturities

The following table summarizes the Company’s operating lease maturities as of December 31, 2023 (in thousands):

Years ending December 31:
2024	$	386
2025		195
2026		55
Total remaining lease payments		636
Less: imputed interest		(47	)
Total lease liabilities	$	589

Business and Geographical Reporting Segments

12 Months Ended

Dec. 31, 2023

Business and Geographical Reporting Segments [Abstract]

Business and Geographical Reporting Segments

15. Business and Geographical Reporting Segments

The Company organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense) is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below (in thousands, except gross profit %):

Year Ended December 31, 2023	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	21,530		$	11,828		$	33,358
Cost of revenues		8,729			6,168			14,897
Gross profit		12,801			5,660			18,461
Gross profit %		59.5	%		47.9	%		55.3	%

Allocated expenses:
Engineering and product development		1,011			306			1,317
Selling and marketing		11,169			1,787			12,956
Impairment of goodwill		2,284			—			2,284
Unallocated expenses		—			—			10,508
		14,464			2,093			27,065
(Loss) income from operations		(1,663	)		3,567			(8,604	)
Interest expense		—			—			(1,640	)
Interest income		—			—			231
Loss on debt extinguishment		—			—			(909	)
(Loss) income before benefit from / (provision for) income taxes	$	(1,663	)	$	3,567		$	(10,922	)

Year Ended December 31, 2022	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	23,025		$	13,136		$	36,161
Cost of revenues		8,371			6,022			14,393
Gross profit		14,654			7,114			21,768
Gross profit %		63.6	%		54.2	%		60.2	%

Allocated expenses:
Engineering and product development		672			357			1,029
Selling and marketing		13,503			1,798			15,301
Unallocated expenses		—			—			10,087
		14,175			2,155			26,417
Income (loss) from operations		479			4,959			(4,649	)
Interest expense		—			—			(926	)
Interest income		—			—			89
Income (loss) before benefit from / (provision for) income taxes	$	479		$	4,959		$	(5,486	)

For the years ended December 31, 2023 and 2022, depreciation and amortization by reportable segment were as follows (in thousands):

	Year Ended December 31,
	2023		2022
Dermatology recurring procedures	$	4,793	$	4,421
Dermatology procedures equipment		746		857
Unallocated expenses		14		15
Total	$	5,553	$	5,293

The following tables present the Company’s revenue disaggregated by geographical region for the years ended December 31, 2023 and 2022 (in thousands). Domestic refers to revenue from customers based in the United States, and foreign revenue is derived from the Company’s distributors primarily in Asia.

Year Ended December 31, 2023	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	20,215	$	2,813	$	23,028
China		—		3,340		3,340
Korea		673		2,055		2,728
Other foreign		642		3,620		4,262
Total	$	21,530	$	11,828	$	33,358

Year Ended December 31, 2022	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	21,585	$	2,396	$	23,981
China		195		4,556		4,751
Korea		888		2,828		3,716
Other foreign		357		3,356		3,713
Total	$	23,025	$	13,136	$	36,161

As of December 31, 2023 and 2022, total assets by reportable segment were as follows (in thousands):

	December 31,
	2023		2022
Dermatology recurring procedures	$	28,137	$	37,230
Dermatology procedures equipment		5,507		7,890
Other unallocated assets		8,372		7,152
Total	$	42,016	$	52,272

Long-lived assets of $0.8 million and $0.6 million were located in international markets, primarily Korea and Japan, as of December 31, 2023 and 2022, respectively, with the remainder located in domestic markets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2023

Income Taxes [Abstract]

Income Taxes

14. Income Taxes

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2023			2022
Current:
Federal	$	—		$	—
State		28			23
		28			23
Deferred:
Federal		(68	)		23
State		(52	)		17
		(120	)		40
(Benefit from) / provision for income taxes	$	(92	)	$	63

Deferred tax assets and liabilities are determined based on the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.

Significant components of the Company’s deferred tax liability for federal income taxes consisted of the following (in thousands):

	December 31,
	2023			2022
Deferred tax assets:
Net operating loss carryforwards	$	46,718		$	45,077
Intangible assets		2,138			1,697
Inventories		71			57
Reserves and accrued expenses		1,381			1,431
Stock-based compensation		180			548
Operating lease liabilities		145			240
Interest expense limitation carryover		552			208
Property and equipment		—			1,111
Gross deferred tax assets		51,185			50,369
Less: valuation allowance		(50,139	)		(49,005	)
		1,046			1,364
Deferred tax liabilities:
Property and equipment		(412	)		—
Operating lease right-of-use assets		(154	)		(242	)
Goodwill		(666	)		(1,095	)
481(a) adjustment		—			(333	)
		(1,232	)		(1,670	)
Net deferred tax liability	$	(186	)	$	(306	)

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a nearly full valuation allowance has been recorded against the Company’s deferred tax assets as of December 31, 2023. The valuation allowance increased by $1.1 million during the year ended December 31, 2023. The Company does not have unrecognized tax benefits as of December 31, 2023 or 2022. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
	2023		2022
Federal	$	205,212	$	198,144
State	$	63,566	$	60,784

The NOL carryforwards generated prior to 2018 began to expire for federal income tax purposes and begin expiring in 2030 for state income tax purposes. Federal and many state NOLs generated in 2018 and into the future now have an indefinite life.

The NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception.

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	Year Ended December 31,
	2023			2022
Federal tax expense at statutory rate		21.00	%		21.00	%
State tax, net of federal benefit		0.18	%		(0.58	)%
Permanent differences		(1.89	)%		(2.23	)%
Other difference and true ups		(8.07	)%		(11.20	)%
Change in valuation allowance		(10.38	)%		(8.14	)%
Effective income tax rate		0.84	%		(1.15	)%

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022 (“IRA”). The IRA contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock repurchases. The provisions of the IRA did not have an impact on the Company’s consolidated financial statements for the year ended December 31, 2023, as the Company currently does not qualify as a large corporation for the 15% alternative minimum tax and there were no stock repurchases during 2023. The Company will monitor its operations for changes that could impact the applicability of the IRA provisions in future tax years.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Business and Geographical Reporting Segments, Depreciation and Amortization by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	$ 5,553	$ 5,293
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	4,793	4,421
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	746	857
Unallocated [Member]
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	$ 14	$ 15

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current [Abstract]
Federal	$ 0	$ 0
State	28	23
Current income tax	28	23
Deferred [Abstract]
Federal	(68)	23
State	(52)	17
Deferred income tax	(120)	40
(Benefit from) / provision for income taxes	(92)	63
Deferred Tax Assets [Abstract]
Net operating loss carryforwards	46,718	45,077
Intangible assets	2,138	1,697
Inventories	71	57
Reserves and accrued expenses	1,381	1,431
Stock-based compensation	180	548
Operating lease liabilities	145	240
Interest expense limitation carryover	552	208
Property and equipment	0	1,111
Gross deferred tax assets	51,185	50,369
Less: valuation allowance	(50,139)	(49,005)
Net deferred tax assets	1,046	1,364
Deferred Tax Liabilities [Abstract]
Property and equipment	(412)	0
Operating lease right-of-use assets	(154)	(242)
Goodwill	(666)	(1,095)
481(a) adjustment	0	(333)
Gross deferred tax liabilities	(1,232)	(1,670)
Net deferred tax liability	(186)	(306)
Valuation allowance - Deferred tax asset change in amount	1,100
Unrecognized tax benefits	$ 0	$ 0
Effective Income Tax Rate Reconciliation [Abstract]
Federal tax expense at statutory rate	21.00%	21.00%
State tax, net of federal benefit	0.18%	(0.58%)
Permanent differences	(1.89%)	(2.23%)
Other difference and true ups	(8.07%)	(11.20%)
Change in valuation allowance	(10.38%)	(8.14%)
Effective income tax rate	0.84%	(1.15%)
Federal [Member]
Operating Loss Carryforwards [Abstract]
Operating loss carryforwards	$ 205,212	$ 198,144
State [Member]
Operating Loss Carryforwards [Abstract]
Operating loss carryforwards	$ 63,566	$ 60,784

Stock-Based Compensation, Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fair Value Assumptions [Abstract]
Expected term (in years)	7 years 5 months 26 days	6 years 1 month 6 days
Expected volatility	74.58%	89.57%
Risk-free interest rate	4.38%	2.51%
Expected dividend rate	0.00%	0.00%

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2023	Mar. 20, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity File Number	0-11635
Entity Registrant Name	STRATA SKIN SCIENCES, INC.
Entity Central Index Key	0001051514
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3986004
Entity Address, Address Line One	5 Walnut Grove Drive
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	Horsham
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19044
City Area Code	215
Local Phone Number	619-3200
Title of 12(b) Security	Common Stock, $0.001 Par Value
Trading Symbol	SSKN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 17,264,756
Entity Common Stock, Shares Outstanding		35,060,920
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	Philadelphia, Pennsylvania

Basis of Presentation and Summary of Significant Accounting Policies, Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restricted Cash [Abstract]
Cash and cash equivalents	$ 6,784	$ 5,434
Restricted cash	1,334	1,361
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$ 8,118	$ 6,795	$ 12,586

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Allowance for credit losses	$ 222	$ 382
Stockholders' equity:
Series C Convertible Preferred Stock, par value (in dollars per share)	$ 0.1	$ 0.1
Series C Convertible Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, shares issued (in shares)	0	0
Series C Convertible Preferred Stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	35,060,920	34,723,046
Common stock, shares outstanding (in shares)	35,060,920	34,723,046

Basis of Presentation and Summary of Significant Accounting Policies, Accrued Warranty Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Activity of Warranty Accrual [Roll Forward]
Balance, beginning of year	$ 207	$ 79
Additions	237	246
Expirations and claims satisfied	(141)	(118)
Total	303	207
Less current portion within accrued expenses and other current liabilities	(180)	(136)
Balance within deferred revenues and other liabilities	$ 123	$ 71
Minimum [Member]
Accrued Warranty Costs [Abstract]
Standard warranty period	1 year
Offered warranty period	3 years
Maximum [Member]
Accrued Warranty Costs [Abstract]
Standard warranty period	2 years
Offered warranty period	4 years

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations [Abstract]
Revenues, net	$ 33,358	$ 36,161
Cost of revenues	14,897	14,393
Gross profit	18,461	21,768
Operating expenses:
Engineering and product development	1,317	1,029
Selling and marketing	12,956	15,301
General and administrative	10,508	10,087
Impairment of goodwill	2,284	0
Total operating expenses	27,065	26,417
Loss from operations	(8,604)	(4,649)
Other (expense) income:
Interest expense	(1,640)	(926)
Interest income	231	89
Loss on debt extinguishment	(909)	0
Other (expense), income net	(2,318)	(837)
(Loss) income before benefit from / (provision for) income taxes	(10,922)	(5,486)
Benefit from / (provision for) income taxes	92	(63)
Net loss	$ (10,830)	$ (5,549)
Net loss per share of common stock - basic (in dollars per share)	$ (0.31)	$ (0.16)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.31)	$ (0.16)
Weighted average shares of common stock outstanding - basic (in shares)	34,920,291	34,712,246
Weighted average shares of common stock outstanding - diluted (in shares)	34,920,291	34,712,246

Business and Geographical Reporting Segments, Disaggregation of Revenue by Geographical Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	$ 33,358	$ 36,161
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	21,530	23,025
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	11,828	13,136
Domestic [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	23,028	23,981
China [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	3,340	4,751
Korea [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	2,728	3,716
Other Foreign [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	4,262	3,713
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	21,530	23,025
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	11,828	13,136
Operating Segments [Member] \| Domestic [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	20,215	21,585
Operating Segments [Member] \| Domestic [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	2,813	2,396
Operating Segments [Member] \| China [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	0	195
Operating Segments [Member] \| China [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	3,340	4,556
Operating Segments [Member] \| Korea [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	673	888
Operating Segments [Member] \| Korea [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	2,055	2,828
Operating Segments [Member] \| Other Foreign [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	642	357
Operating Segments [Member] \| Other Foreign [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	$ 3,620	$ 3,356

- Definition

+ References

+ Details

Basis of Presentation and Summary of Significant Accounting Policies, Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Advertising Costs [Abstract]
Advertising expense	$ 0.5	$ 1.6

Business and Geographical Reporting Segments, Results of Operations from Business Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Segment	Dec. 31, 2022 USD ($)
Business Segments [Abstract]
Number of operating segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 33,358	$ 36,161
Cost of revenues	14,897	14,393
Gross profit	$ 18,461	$ 21,768
Gross profit %	55.30%	60.20%
Allocated expenses [Abstract]
Engineering and product development	$ 1,317	$ 1,029
Selling and marketing	12,956	15,301
Impairment of goodwill	2,284	0
Unallocated expenses	10,508	10,087
Total operating expenses	27,065	26,417
Loss from operations	(8,604)	(4,649)
Interest expense	(1,640)	(926)
Interest income	231	89
Loss on debt extinguishment	(909)	0
(Loss) income before benefit from / (provision for) income taxes	(10,922)	(5,486)
Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	21,530	23,025
Allocated expenses [Abstract]
Impairment of goodwill	2,300
Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	11,828	13,136
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	21,530	23,025
Cost of revenues	8,729	8,371
Gross profit	$ 12,801	$ 14,654
Gross profit %	59.50%	63.60%
Allocated expenses [Abstract]
Engineering and product development	$ 1,011	$ 672
Selling and marketing	11,169	13,503
Impairment of goodwill	2,284
Unallocated expenses	0	0
Total operating expenses	14,464	14,175
Loss from operations	(1,663)	479
Interest expense	0	0
Interest income	0	0
Loss on debt extinguishment	0
(Loss) income before benefit from / (provision for) income taxes	(1,663)	479
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	11,828	13,136
Cost of revenues	6,168	6,022
Gross profit	$ 5,660	$ 7,114
Gross profit %	47.90%	54.20%
Allocated expenses [Abstract]
Engineering and product development	$ 306	$ 357
Selling and marketing	1,787	1,798
Impairment of goodwill	0
Unallocated expenses	0	0
Total operating expenses	2,093	2,155
Loss from operations	3,567	4,959
Interest expense	0	0
Interest income	0	0
Loss on debt extinguishment	0
(Loss) income before benefit from / (provision for) income taxes	$ 3,567	$ 4,959

Property and Equipment, net

12 Months Ended

Dec. 31, 2023

Property and Equipment, net [Abstract]

Property and Equipment, net

6. Property and Equipment, net

Property and equipment consist of the following (in thousands):

	December 31,
	2023			2022
Lasers placed-in-service	$	32,095		$	28,790
Equipment, computer hardware and software		293			293
Furniture and fixtures		240			235
Leasehold improvements		203			136
Lasers-in-process		3,231			2,452
		36,062			31,906
Less: accumulated depreciation and amortization		(24,284	)		(21,956	)
	$	11,778		$	9,950

The Company recorded depreciation and amortization expense of $2.9 million and $2.4 million during the years ended December 31, 2023 and 2022, respectively.

Asset Acquisition (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
Asset Acquisition (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2023
Acquisition of Assets and Liabilities [Abstract]
Number of shares issued in connection with asset acquisition (in shares)			358,367
Assets acquired [Abstract]
Reduction in contingent consideration adjusted to carrying value of technology intangible asset			$ 7,400
Maximum [Member]
Acquisition of Assets and Liabilities [Abstract]
Future earnout milestone payments	$ 500
Future milestone payments	3,000
Maximum [Member] \| Domestic [Member]
Acquisition of Assets and Liabilities [Abstract]
Future royalty payments	$ 500
TheraClear Corporation [Member]
Acquisition of Assets and Liabilities [Abstract]
Number of shares issued in connection with asset acquisition (in shares)	358,367
Milestone payments		$ 500
Future earnout payment due upon revenue target	$ 1,000
Royalty and gross profit payments incurred			$ 100
Consideration [Abstract]
Cash payment	500
Common stock issued	500
Transaction costs	131
Contingent consideration	9,122
Total consideration	10,253
Assets acquired [Abstract]
Inventories	71
Total assets acquired	$ 10,253
Weighted average cost of capital	14.50%
Revenues for the royalty rate	15.00%
Risk free rate of return	1.60%		3.80%
Revenue volatility	45.00%		15.00%
Cost of equity	10.50%		10.00%
Fair value of contingent consideration			$ 1,200
Reduction in contingent consideration adjusted to carrying value of technology intangible asset			$ (7,400)
TheraClear Corporation [Member] \| Technology [Member]
Assets acquired [Abstract]
Intangible asset	$ 10,182
Amortization period of intangible assets			10 years
TheraClear Corporation [Member] \| Foreign [Member]
Acquisition of Assets and Liabilities [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	25.00%
Subsequent period of gross profit for future royalty payments			4 years
TheraClear Corporation [Member] \| Minimum [Member] \| Domestic [Member]
Acquisition of Assets and Liabilities [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	10.00%
TheraClear Corporation [Member] \| Maximum [Member]
Acquisition of Assets and Liabilities [Abstract]
Future earnout milestone payments	$ 3,000
Future milestone payments	500
TheraClear Corporation [Member] \| Maximum [Member] \| Domestic [Member]
Acquisition of Assets and Liabilities [Abstract]
Future royalty payments	$ 20,000
Percentage of gross profit for future royalty payments for subsequent period	20.00%

Stock-Based Compensation, Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-Based Compensation Expense [Abstract]
Stock-based compensation expense	$ 1,303	$ 1,466
Selling and Marketing [Member]
Stock-Based Compensation Expense [Abstract]
Stock-based compensation expense	79	203
General and Administrative [Member]
Stock-Based Compensation Expense [Abstract]
Stock-based compensation expense	$ 1,224	$ 1,263

Long-term Debt

12 Months Ended

Dec. 31, 2023

Long-term Debt [Abstract]

Long-term Debt

10. Long-Term Debt

On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust (“MidCap”), also acting as the administrative agent, and the lenders identified therein. The original terms provided for an $8.0 million senior term loan. Borrowings under the senior term loan originally bore interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and were scheduled to mature on September 1, 2026, unless terminated earlier. The Company was obligated to make monthly interest-only payments through September 30, 2024. The credit and security agreement was amended on January 10, 2022 to provide MidCap’s consent to the TheraClear asset acquisition (Note 3). On September 6, 2022, the Company amended the facility to transition, upon the cessation of LIBOR, to one-month Secured Overnight Financing Rate (“SOFR”), or such other applicable period, plus 0.10%, with a floor of 0.50%.

On June 30, 2023, the Company entered into (a) Amendment No. 3 to the credit and security agreement (the “Third Amendment”); (b) the Amended and Restated Warrant Agreement (the “A&R Warrant”) with MidCap Funding XXVII Trust (together with any registered holder from time to time or any holder of the shares issuable or issued upon the exercise or conversion of the warrant, the “Warrantholder”), which amended and restated the warrant agreement to purchase shares of the common stock of the Company, dated as of September 30, 2021 (the “Prior Warrant”), with the Warrantholder; (c) the Amended and Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”) with the Warrantholder, which amended and restated the registration rights agreement, dated as of September 30, 2021, with the Warrantholder; and (d) a letter agreement (the “Fee Letter Agreement”) with MidCap, as agent.

On February 20, 2024, the Company entered into (a) Amendment No. 4 to the credit and security agreement (the “Fourth Amendment”) which amended the credit and security agreement (as amended by the Third and Fourth Amendments, the “Senior Term Facility”), and (b) a second amended and restated letter agreement (“Amended Fee Letter Agreement”) with MidCap, as agent.

On March 27, 2024, the Company entered into Amendment No. 5 to the credit and security agreement, which clarified certain provisions related to the maintenance of cash collateral accounts.

The Senior Term Facility provides for a senior secured term loan facility of $20.0 million, of which $8.0 million was drawn by the Company on September 30, 2021 (“Credit Facility #1”), $7.0 million was drawn by the Company on June 30, 2023 (“Credit Facility #2”), and an additional $5.0 million tranche (“Credit Facility #3”) is available to be drawn by the Company if its Dermatology Recurring Procedures Revenue (as defined in the Senior Term Facility) for the preceding 12 calendar months (ending on the last day of the calendar month for which a compliance certificate is delivered) is greater than or equal to $30.0 million (such condition, the “Applicable Funding Condition”). Credit Facility #3 can be drawn beginning on the later of the satisfaction of the Applicable Funding Condition and January 1, 2024, with such commitment terminating on the earlier to occur of December 31, 2024 and the delivery of a written notice by MidCap to the Company terminating the applicable commitments following an Event of Default (as defined in the Senior Term Facility) that has not been waived or cured at the time such notice is delivered. All borrowings are secured by substantially all of the Company’s assets.

Borrowings under the Senior Term Facility bear interest at a rate per annum equal to the sum of (a) the greater of (i) the sum of (A) 30-day forward-looking term rate of one month SOFR, as published by CME Group Benchmark Administration Limited, from time to time, plus (B) 0.10%, and (ii) the applicable floor rate of 3.50%, with such sum reset monthly, and (b) 7.50%. The effective interest rate of the Senior Term Facility as of December 31, 2023 and 2022 was 13.68% and 11.72%, respectively. The Company is obligated to make interest-only payments (payable monthly in arrears) through June 1, 2026. Commencing on July 1, 2026 and continuing for the remaining 24 months of the facility, the Company will be required to make monthly interest payments and monthly principal payments based on a straight-line amortization schedule set forth in the Senior Term Facility, subject to certain adjustments as described in the Senior Term Facility. The final maturity date under the Senior Term Facility is June 1, 2028, unless earlier terminated. The Senior Term Facility requires the Company to dedicate 100% of certain insurance proceeds to the prepayment of the outstanding term loan, subject to certain exceptions and net of certain expenses and repayments.

The Company may voluntarily prepay the outstanding term loan under the Senior Term Facility, with such prepayment in an amount of at least $5.0 million, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 4.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made within 12 months of February 20, 2024, (ii) 3.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 12 months and 24 months after February 20, 2024, (iii) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after February 20, 2024, or (iv) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made after 36 months after February 20, 2024 and prior to the maturity date.

The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions, as well as various negative covenants. Further, the Senior Term Facility contains (a) a quarterly financial covenant that requires the Company to not have less than $29.0 million of net revenue (raised to $33.0 million by December 31, 2026 and, for periods ending after December 31, 2026, such net revenue as determined in good faith by MidCap, which shall not be less than the applicable minimum net revenue amount for the immediately preceding period and $33.0 million) for the trailing 12-month period as of March 31, 2024, and (b) a minimum of unrestricted cash (as defined in the Senior Term Facility), at all times, of not less than $3.0 million. Prior to the execution of the Fourth Amendment, the minimum net revenue threshold was $36.0 million for the trailing 12-month period as of December 31, 2023, which the Company did not meet. Through the Fourth Amendment, MidCap granted a limited waiver of this event of default that occurred as of December 31, 2023 and of any right MidCap had to exercise its rights against the Company as a result. At December 31, 2023, the Company was in compliance with all other financial covenants within the Senior Term Facility.

Upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, (i) suspend or terminate the term loan commitment and MidCap and the other lenders’ obligations with respect thereto, and (ii) by notice to the Company, declare all or any portion of the obligations under the Senior Term Facility to be immediately due and payable. In addition to MidCap’s other rights and available remedies, but subject to applicable cure periods, upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, terminate the Senior Term Facility. Given that the Fourth Amendment granted a limited waiver as described above, as of December 31, 2023, the Company believed that events or conditions having a material adverse effect, giving rise to an acceleration of any amounts outstanding under the Senior Term Facility, had not occurred and was remote.

Pursuant to the Amended Fee Letter Agreement, the Company agreed to pay MidCap, as administrative agent, the following fees: (a) an origination fee on June 30, 2023 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #2, multiplied by (ii) 0.50%; (b) on the maturity date of the Senior Term Facility or any earlier date on which the obligations thereunder become due and payable in full or are otherwise paid in full (such date, the “Full Exit Fee Payment Date”), the Company shall pay an exit fee equal to (i) 4.00% of the total aggregate principal amount of Credit Extensions (as defined in the Senior Term Facility) made pursuant to the Senior Term Facility (regardless of any repayment or prepayment thereof) as of the Full Exit Fee Payment Date (such aggregate amount, the “Exit Fee Base Amount”), less (ii) any Partial Exit Fee (as defined below) previously paid; (c) on the date of any voluntary or mandatory partial prepayment of the borrowings under the Senior Term Facility (or on the date such mandatory prepayment becomes due and payable) (each such date, a “Partial Exit Fee Payment Date”), the Company shall pay an exit fee equal to 4.00% of the principal amount of the credit facilities paid or prepaid (or required to be paid in the case of a mandatory prepayment) as of the Partial Exit Fee Payment Date (such amount, the “Partial Exit Fee”); and (d) an origination fee payable contemporaneously with funding Credit Facility #3 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #3, multiplied by (ii) 0.50%.

The Prior Warrant allowed the Warrantholder, an affiliate of the lender, to purchase 373,626 shares of the Company’s common stock at an exercise price equal to $1.82 per share for a 10-year period ending September 30, 2031. Pursuant to, and in accordance with, the terms and conditions of the A&R Warrant, which amended and restated the Prior Warrant, the Warrantholder can purchase 800,000 shares of the Company’s common stock at an exercise price equal to $0.88 per share for a 10-year period ending on June 30, 2033. Pursuant to the A&R Registration Rights Agreement, the Company registered the shares underlying the A&R Warrant effective August 18, 2023. The amendment of the warrant resulted in an increase in the fair value of the warrant, which has been accounted for as a lender fee.

The Third Amendment has been accounted for as a debt extinguishment, as the new loan is considered substantially different from the original loan. The Company recorded a loss on debt extinguishment of $0.9 million for the year ended December 31, 2023, which includes unamortized debt discount on the original loan of $0.4 million, an increase in the fair value of the warrant of $0.4 million and lender fees of $0.1 million. In connection with the Third Amendment, the Company recorded the $0.5 million exit fee (equal to 3.00% of the aggregate principal amount of Credit Extensions #1 and #2 prior to execution of the Fourth Amendment) as both a debt discount and an increase to the principal amount of the debt. The debt discount, which also includes third party costs incurred in connection with the Third Amendment of $13 thousand, is being recognized as interest expense over the term of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $0.4 million and $0.5 million as of December 31, 2023 and 2022, respectively. The Company recognized interest expense of $1.6 million during the year ended December 31, 2023, of which $0.1 million was related to the amortization of the debt discount. The Company recognized interest expense of $0.9 million during the year ended December 31, 2022, of which $0.2 million was related to the amortization of the debt discount.

Future minimum principal payments at December 31, 2023 are as follows (in thousands):

Years ending December 31:
2026	$	3,750
2027		7,500
2028		3,750
		15,000
Exit fee		450
		15,450
Less: unamortized debt discount		(406	)
Long-term debt, net	$	15,044

Intangible Assets and Goodwill, Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Estimated amortization expense [Abstract]
2024	$ 1,971
2025	1,266
2026	561
2027	561
2028	$ 561

Commitments and Contingencies (Details) $ in Millions		1 Months Ended	12 Months Ended
Commitments and Contingencies (Details) $ in Millions	Feb. 23, 2023 USD ($)	Jan. 31, 2022 USD ($) Device	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Legal Matters [Abstract]
Litigation settlement to be paid	$ 0.1
Litigation settlement accrued			$ 0.1
Employee 401(k) Savings Plan [Abstract]
Employer contribution amount			$ 0.4	$ 0.3
Milestone Payment [Abstract]
Development agreement term			3 years
Maximum [Member]
Milestone Payment [Abstract]
Number of devices in development \| Device		3
Future earnout payments		$ 0.5
Future milestone payments		3.0
Domestic [Member] \| Maximum [Member]
Milestone Payment [Abstract]
Future royalty payments		$ 0.5
Tax Period from March 2014 through November 2022 [Member]
Sales and Use Tax Matters [Abstract]
Estimated tax positions subject to audit			$ 3.9
Tax Period from March 2014 through November 2022 [Member] \| Assessment One [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount			1.4
Tax Period from March 2014 through November 2022 [Member] \| Assessment Two [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount			$ 2.5

Asset Acquisition (Tables)

12 Months Ended

Dec. 31, 2023

Asset Acquisition [Abstract]

Purchase Price Allocation

The purchase price was allocated, on a relative fair value basis, to the technology intangible asset and acquired inventories as follows (in thousands):

Consideration:
Cash payment	$	500
Common stock issued		500
Transaction costs		131
Contingent consideration		9,122
Total consideration	$	10,253

Assets acquired:
Technology intangible asset	$	10,182
Inventories		71
Total assets acquired	$	10,253

Basis of Presentation and Summary of Significant Accounting Policies, Concentrations of Credit Risk and Major Customers (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Customer	Dec. 31, 2022 USD ($) Customer
Concentration of Credit Risk [Abstract]
Revenues	$ 33,358	$ 36,161
Accounts receivable	$ 4,440	$ 4,471
Customer Concentration Risk [Member] \| Revenue [Member]
Concentration of Credit Risk [Abstract]
Number of major customers \| Customer	1	2
Customer Concentration Risk [Member] \| Revenue [Member] \| One Customer [Member]
Concentration of Credit Risk [Abstract]
Revenues	$ 3,300
Concentration risk percentage	10.00%
Customer Concentration Risk [Member] \| Revenue [Member] \| Two Customers [Member]
Concentration of Credit Risk [Abstract]
Revenues		$ 8,500
Concentration risk percentage		23.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| One Customer [Member]
Concentration of Credit Risk [Abstract]
Accounts receivable	$ 0
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Two Customers [Member]
Concentration of Credit Risk [Abstract]
Accounts receivable		$ 500
Concentration risk percentage		11.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Other Customer [Member]
Concentration of Credit Risk [Abstract]
Number of major customers \| Customer	1
Accounts receivable	$ 700
Concentration risk percentage	16.50%

Leases

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

7. Leases

The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than 12 months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from one to three years, and one facility lease had a renewal option for two years. The renewal option was initially excluded from the determination of the lease term as it was not reasonably certain of exercise. In August 2022, the Company exercised the renewal option and amended the terms of the option, which has been accounted for as a lease modification. The ROU asset and operating lease liability were remeasured at the modification date, resulting in an increase to both balances of $0.7 million during the year ended December 31, 2022. There were no lease modifications during the year ended December 31, 2023.

Operating lease costs were $0.4 million for each of the years ended December 31, 2023 and 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $0.4 million for each of the years ended December 31, 2023 and 2022. As of December 31, 2023 and 2022, the weighted average incremental borrowing rate was 8.60% and 8.76%, respectively, and the weighted average remaining lease term was 2.0 years and 2.8 years, respectively.

The following table summarizes the Company’s operating lease maturities as of December 31, 2023 (in thousands):

Years ending December 31:
2024	$	386
2025		195
2026		55
Total remaining lease payments		636
Less: imputed interest		(47	)
Total lease liabilities	$	589

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the lessee arrangement as a single lease component.

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2023

Intangible Assets and Goodwill [Abstract]

Intangible Assets and Goodwill

8. Intangible Assets and Goodwill

Intangible assets consist of the following (in thousands):

December 31, 2023	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(4,845	)	$	855
Product technology		4,808		(3,866	)		942
Customer relationships		6,900		(5,865	)		1,035
Tradenames		1,500		(1,275	)		225
Pharos customer lists		5,314		(1,052	)		4,262
	$	24,222	$	(16,903	)	$	7,319

December 31, 2022	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(4,275	)	$	1,425
Product technology		12,182		(3,018	)		9,164
Customer relationships		6,900		(5,175	)		1,725
Tradenames		1,500		(1,125	)		375
Pharos customer lists		5,314		(609	)		4,705
	$	31,596	$	(14,202	)	$	17,394

The Company recorded amortization expense of $2.7 million and $2.9 million during the years ended December 31, 2023 and 2022, respectively.

During the year ended December 31, 2023 the Company recognized an adjustment of $7.4 million to the carrying value of product technology as a result of the revaluation of contingent consideration related to the TheraClear asset acquisition (Note 3).

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2024			1,971
2025			1,266
2026			561
2027			561
2028			561

Goodwill consists of the following (in thousands):

	December 31,
	2023		2022
Dermatology recurring procedures segment	$	5,674	$	7,958
Dermatology procedures equipment segment		845		845
	$	6,519	$	8,803

During the year ended December 31, 2023, the Company recognized a goodwill impairment charge of $2.3 million related to the dermatology recurring procedures segment primarily driven by a decline in projected cash flows, including revenues and profitability (see Note 2).

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events On February 20, 2024, the Company amended its credit and security agreement and fee letter agreement with MidCap. On March 27, 2024, the Company further amended its credit and security agreement with MidCap. See Note 10 for details.

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Contract Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Contract with Customer, Liability [Abstract]
Short-term contract liabilities	$ 0.3	$ 0.4
Long-term contract liabilities	0.4	0.2
Change in Contract with Customer, Liability [Abstract]
Contract liabilities recognized as revenue	$ 0.4	$ 0.9

Stock-Based Compensation, Summary (Details) - USD ($) $ in Millions			1 Months Ended	12 Months Ended
	Apr. 03, 2023	Mar. 30, 2022	Oct. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Stock-based Compensation [Abstract]
Unvested options to purchase shares of common stock accelerated (in shares)			272,098
Accelerated compensation expense			$ 0.3
Stock Options [Member]
Stock-based Compensation [Abstract]
Granted (in shares)				4,545,069	1,000,000
Stock-based options forfeited (in shares)					60,000
Stock Options [Member] \| Chief Executive Officer [Member]
Stock-based Compensation [Abstract]
Granted (in shares)	150,000	160,000
Stock-based options forfeited (in shares)				150,000
2016 Omnibus Incentive Plan [Member]
Stock-based Compensation [Abstract]
Common stock reserved for future issuance (in shares)				7,832,651
Number of shares available for issuance (in shares)				1,329,375

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2023		2022
Cash and cash equivalents	$	6,784	$	5,434
Restricted cash		1,334		1,361
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,118	$	6,795

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2023 and 2022 is summarized as follows (in thousands):

	December 31,
	2023			2022
Balance, beginning of year	$	207		$	79
Additions		237			246
Expirations and claims satisfied		(141	)		(118	)
Total		303			207
Less current portion within accrued expenses and other current liabilities		(180	)		(136	)
Balance within deferred revenues and other liabilities	$	123		$	71

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2023		2022
Dermatology recurring procedures	$	21,530	$	23,025
Dermatology procedures equipment		11,828		13,136
Total net revenues	$	33,358	$	36,161

Future Undiscounted Fixed Treatment Code Payments

Years ending December 31:
2024	$	1,319
2025		787
2026		569
2027		298
	$	2,973

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2023		2022
Stock options		7,728,721		4,474,714
Common stock warrants		800,000		373,626
Restricted stock units		22,654		278,004
		8,551,375		5,126,344

Basis of Presentation and Summary of Significant Accounting Policies, Intangible Assets (Details)	Dec. 31, 2023
Minimum [Member]
Intangible Assets [Abstract]
Estimated useful life	3 years
Maximum [Member]
Intangible Assets [Abstract]
Estimated useful life	12 years

Business and Geographical Reporting Segments (Tables)

12 Months Ended

Dec. 31, 2023

Business and Geographical Reporting Segments [Abstract]

Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below (in thousands, except gross profit %):

Year Ended December 31, 2023	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	21,530		$	11,828		$	33,358
Cost of revenues		8,729			6,168			14,897
Gross profit		12,801			5,660			18,461
Gross profit %		59.5	%		47.9	%		55.3	%

Allocated expenses:
Engineering and product development		1,011			306			1,317
Selling and marketing		11,169			1,787			12,956
Impairment of goodwill		2,284			—			2,284
Unallocated expenses		—			—			10,508
		14,464			2,093			27,065
(Loss) income from operations		(1,663	)		3,567			(8,604	)
Interest expense		—			—			(1,640	)
Interest income		—			—			231
Loss on debt extinguishment		—			—			(909	)
(Loss) income before benefit from / (provision for) income taxes	$	(1,663	)	$	3,567		$	(10,922	)

Year Ended December 31, 2022	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	23,025		$	13,136		$	36,161
Cost of revenues		8,371			6,022			14,393
Gross profit		14,654			7,114			21,768
Gross profit %		63.6	%		54.2	%		60.2	%

Allocated expenses:
Engineering and product development		672			357			1,029
Selling and marketing		13,503			1,798			15,301
Unallocated expenses		—			—			10,087
		14,175			2,155			26,417
Income (loss) from operations		479			4,959			(4,649	)
Interest expense		—			—			(926	)
Interest income		—			—			89
Income (loss) before benefit from / (provision for) income taxes	$	479		$	4,959		$	(5,486	)

Disaggregation of Revenue by Geographical Region

Year Ended December 31, 2023	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	20,215	$	2,813	$	23,028
China		—		3,340		3,340
Korea		673		2,055		2,728
Other foreign		642		3,620		4,262
Total	$	21,530	$	11,828	$	33,358

Year Ended December 31, 2022	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	21,585	$	2,396	$	23,981
China		195		4,556		4,751
Korea		888		2,828		3,716
Other foreign		357		3,356		3,713
Total	$	23,025	$	13,136	$	36,161

Depreciation and Amortization by Reportable Segment

For the years ended December 31, 2023 and 2022, depreciation and amortization by reportable segment were as follows (in thousands):

	Year Ended December 31,
	2023		2022
Dermatology recurring procedures	$	4,793	$	4,421
Dermatology procedures equipment		746		857
Unallocated expenses		14		15
Total	$	5,553	$	5,293

Total Assets by Reportable Segment

As of December 31, 2023 and 2022, total assets by reportable segment were as follows (in thousands):

	December 31,
	2023		2022
Dermatology recurring procedures	$	28,137	$	37,230
Dermatology procedures equipment		5,507		7,890
Other unallocated assets		8,372		7,152
Total	$	42,016	$	52,272

Basis of Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Maximum [Member]
Cash and Cash Equivalents [Abstract]
Credit card transaction settlement term	5 days	5 days

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2023

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

9. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2023		2022
Warranty obligations	$	180	$	136
Compensation and related benefits		1,679		1,997
State sales, use and other taxes		4,316		3,986
Professional fees and other		131		436
	$	6,306	$	6,555